Windham Venture Partners focuses on early-stage investments at the intersection of medical technology and digital health, aiming to improve clinical outcomes and address inefficiencies within the healthcare system. The firm employs a founder-friendly strategy, providing both capital and strategic guidance and operational support to its portfolio companies.
80% of their portfolio is in Healthcare. They made 1 investments in the last 12 months. Average disclosed round size is $54.2M (across 8 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Growth
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 PainTEQ | Growth | — | Aug 2025 |
 Valera Health | Growth | $44.5M | Oct 2022 |
| Valera Health | Seed | $3.8M | Feb 2021 |
 DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
 Neuspera Medical | Series B | $26M | Feb 2019 |
 Nuvaira | Series C | $79M | Feb 2019 |
 Personal Genome Diagnostics Inc. (PGDx) | Series B | $75M | Jan 2018 |
 Earlens Corporation, Inc. | Series C | $73M | Jun 2017 |
| PainTEQ | Unknown | — | — |
 Alto Neuroscience | Series A | $32M | — |
Top Co-Investors
AXA Venture Partners2 shared
Lightstone Ventures2 shared
Heritage Group1 shared
Cigna Ventures1 shared
Aquiline1 shared
U.S. Venture Partners1 shared
Endeavour Vision1 shared
Split Rock Partners1 shared
Versant Ventures1 shared
Vertex Growth Fund1 shared
OrbiMed1 shared
Menlo Ventures1 shared
Samsara BioCapital1 shared
Illumina Ventures1 shared
AV8 Ventures1 shared
Foresite Capital1 shared
Northpond Ventures1 shared
Cowen Healthcare Investments1 shared
Rock Springs Capital1 shared
T. Rowe Price Associates, Inc.1 shared
Last updated: 8 March 2026